Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 347 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... July 2, 2020 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Câncer em minha comunidade: Trabalhando para expandir o acesso a estudos... September 22, 2022 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... September 23, 2024 Load more HOT NEWS Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia Breast Cancer Survivor Driven from Her Home by Noxious Gases from... Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following...
